Sitemap
- Home
- Diabetes
- Integrated Diabetes Care
- Articles
- A narrative review for clinicians on insulin management for Type 2 Diabetes during Ramadan
- Real world Evidences
- ATTD 2021: Patients’ profiles for digital tools
- A Cross-Sectional Analysis of Glycemic Control in Elderly People with Type 2 Diabetes Attending Primary Health Care Unit
- Impact of Time-In-Range on Diabetes Management
- EVOLUTION: RWE from Saudi Arabia
- Time-In-Range (TIR): How to interpret it and how it is associated with outcomes
- National Diabetes Training Program For Primary health care physicians in KSA
- New technologies in Type 2 Diabetes management and future opportunities to improve clinical outcomes
- Expert consensus statement on management of older adults with type 2 diabetes (T2D)
- Single injectable treatment may not be enough to get T2DM patient to Glycemic goal
- Diabetes Your Type: Testimonial by Dr. Bassam
- Diabetes your type: Testimonial by Dr. Nadia
- Prevalence of Diabetes in Children and Adolescents
- The InRange Study
- The burden associated with insulin self-management
- Connectivity Canvas: Pioneering Diabetes Management with Connected Insulin Caps
- Post-exercise hypoglycemia in relation to medication regimen among adults with type 2 diabetes
- Do historical HbA1c values explain glycemic legacy effect in type 2 diabetes?
- Titration Inertia; A Predominant Issue for People with Diabetes
- The Bright Study
- Challenges associated with commonly-used insulin advancement options
- What Is Time-in-Range?
- Unveiling Significance of Time in Range: Value as key Glycemic Biomarker
- Management of athletes and active people with diabetes - The American Medical Society for Sports Medicine (AMSSM) scientific statement
- Diabetes management during Ramadan
- Inside Diabetes: ATTD Edition | Type 2 Diabetes
- Patient awareness and attainment of goals in Type 2 Diabetes Mellitus: A real-world survey
- Understanding Time-in-Range: Assessment, Targets, and Benefits for Optimal Glycemic Control
- Time-in-Range: A Key Determinant of Quality of Life
- Need to redefine the treatment paradigm Post OAD
- Insulin advancement in Type 2 diabetes: Unmet needs with commonly-used options
- The value of Time-in-range
- EMPOWER Study in Saudi Arabia
- Diabetes your type: Testimonial by Dr. Hussein
- The Lixilan-L Study
- Reducing risk of severe hypoglycemia - iNPHORM Study
- The Evolving Role of Treatment and Technology in Diabetes Care
- Hospitalization Rates for Acute Diabetes Complications Before and After Flash Glucose Monitoring Initiation Among People with Type 1 or Type 2 Diabetes in France: The Relief Study
- Resources
- My Dose Coach - Self Titration
- My Dose Coach Inquiry
- Impact of the Frequency of My Dose CoachTM Use on Clinical Outcomes in Type 2 Diabetes
- My Dose Coach - About MDC
- My Dose Coach - Register your Clinic
- My Dose Coach - Patient Guide
- My Dose Coach - Real World Evidence
- Hypoglycemia
- My Dose Coach
- My Dose Coach - Getting Started
- About Diabetes
- Insulin titration and technology-based solutions
- Events
- GAED 2023
- Safe & Smart - Dr. Kalra
- Nutrition and Insulin management in Ramadan
- Amaryl Safe & Smart: Cardio Safe & Gluco Smart Approach in Diabetes Management
- Cardiometabolic Approach in Diabetes Management
- World Diabetes Day
- Safe & Smart - Dr. Khudhair
- Safe & Smart: Cardio Safe & Gluco Smart Approach in Diabetes Management
- Dia-Tour: Navigating New Destinations in Diabetes Management
- Navigate new destinations in diabetes management
- Safe & Smart - Dr. Nabil
- Diatour Inquiry Form
- Safe & Smart - Dr. Salah
- Leveraging Time-In-Range to Improve Patient Experience
- Diabetes Guidelines in Ramadan
- Type 2 Diabetes Cost Effective Management
- Articles
- Type 2 Diabetes
- Articles
- Insulin Treatment Intensification with GLP - 1RA vs Basal - Plus/Basal - Bolus Regimens
- Unmet needs in adults with T2D receiving premixed insulin
- SoliCGM Synergy: Soliqua’s Synchronized Impact on T2DM CGM Dynamics Therapy
- iGlarLixi Enables Safe Ramadan Fasting for Most T2D Patients
- ADA 2021: Solimix Trial Summary
- Advancing Therapy with iGlarLixi: Differentiation from complex insulin regimens
- SoliMix Study Results Summary
- Advancing Therapy with iGlarLixi
- New 2022 ADA/EASD Guidelines: GLPP-1 RA/Insulin Combination Is Recommended
- Advancing therapy in suboptimally controlled basal insulin-treated type 2 diabetes: Clinical outcomes with iGlarLixi versus premix BIAsp 30 in the SoliMix randomized controlled trial.
- Recommendations on treatment simplification of complex insulin regimens to improve clinical outcomes in patients with T2DM
- The ATOS Study: Real-World Study on Effectiveness of Insulin Glargine U300 in the Gulf Region.
- Treatment simplification for adults with Type 2 diabetes
- The SoliRam observational study
- Treatment simplification in T2D: A less-is-more approach to help reduce the burden of disease
- Effectiveness of continuous glucose monitoring in adults with Type 2 diabetes treated with basal insulin
- Treatment simplification of complex insulin regimens in T2D
- ATTD 2021: Technology Supporting Initiation, Titration, and Intensification
- Groundbreaking SoliD Study: Comparative Efficacy of iGlarLixi and IDegAsp
- Basal Insulin and Beyond: Advanced Therapies for Type 2 Diabetes
- Glargine 300 use in people with type 2 diabetes who fast during Ramadan
- SoliD: Redefine Treatment Paradigm Post-OAD
- An Evidence about The Role of Basal Insulin Glargine 300 U/mL Post-GLP-1 Therapy
- Advancing Therapy with iGlarLixi: Differentiation from other complex regimens
- Is Premixed Insulin an Effective Treatment for Type 2 Diabetes Uncontrolled by OADs?
- Resources
- Events
- Articles
- Type 1 Diabetes
- Articles
- Closed-loop insulin delivery during exercise in people with T1DM
- Exploring the risk for severe hypoglycemia in the pool of studied patients with T1D
- Summary of SAGE study on Adults with T1DM
- T1DM Mini-Series: How to Avoid Hypoglycaemia in People with T1 Diabetes?
- T1DM Mini-Series: Relevance of Edition JUNIOR trial results for the HCP and Patient life
- Why to screen for Autoimmune T1D
- How to screen for Autoimmune T1D
- T1DM Mini-Series: Clinical implications of having hyperglycaemia with ketosis
- Inside Diabetes: ATTD Edition | Type 1 Diabetes
- Edition Junior Study - Helping patients with type 1 diabetes (T1D) to find better treatment options
- T1DM Mini-Series: Severe hypoglycaemia compromises the achievement of glycaemic control
- T1DM Mini-Series: How does Hypoglycaemia impact the life of people with T1 Diabetes?
- The burden of Autoimmune T1D
- Understanding Autoimmune T1D disease & Different Stages
- T1D Treatment Practice and the SAGE Study
- T1DM Mini-Series: The main challenge for the kids and adolescents with T1
- T1DM Mini-Series: Edition Junior trial results
- Articles
- Other Diabetes Topics
- Integrated Diabetes Care
- Cardiology
- Dyslipidemia
- Articles
- Odyssey outcomes - CVOT mortality sub-analysis
- Odyssey outcomes
- LDL-C Targets in Patients with Heterozygous Familial Hypercholesterolemia
- Act Now for Your ACS Patients: Optimize Your ACS Pathway
- Act Now for Your ACS Patients: Summary
- Key Learnings in Dyslipidemia by Prof. Kausik Ray - 2021 EAS Congress
- Achievement of ESC/EAS LDL-C Treatment Goals After an ACS with Statin and Alirocumab
- Cardiovascular diseases (CVDs) are the leading cause of death globally¹
- PCSK9 Inhibitors in Real World Practice
- The ROSETTE Study
- Italian real-world analysis for PCSK9 inhibitors new users
- Approach for Patients with PAD and T2D: Focus on LDL-C Control
- PCSK9 inhibitors and ACS
- Identifying and treating patients with high Lipidaemia risk post-ACS
- Atherosclerotic Cardiovascular Disease Risk Assessment
- APSC Consensus Recommendations on Dyslipidemia
- Hypercholesterolemia Treatment Patterns and Lipid Target in ACS Patients: HYDRA-ACS Registry
- Why compromise for less: Should PCSK9 inhibitors be initial therapy?
- PCSK9 Inhibitors in Cardiovascular Disease
- Prophylactic Strategies for VTE in Gynecologic Cancer Patients
- Treating to target in clinical practice: Why is it important to achieve recommended LDL-C levels?
- Managing the Recurrent ASCVD Risks of Your ACS Patient: Gulf Perspective (Part 1)
- Statin/ezetimibe SPC for better adherence to LLT
- The role of the patient in Achieving LDL-C Target
- Odyssey outcomes - DM sub-analysis
- Odyssey Outcomes - Total Events Analysis
- Managing the Recurrent ASCVD Risks of Your ACS Patient: A call to Action – GULF Perspective: Part 3
- ESC/EAS 2019 international guidelines
- Lp(a) as ASCVD risk factor
- Act Now for Your ACS Patients: Treat Aggressively, Combine and Start Early
- LLTs and Antithrombotic Therapy in PAD
- Odyssey outcomes - total events results
- The Explorer Study
- Public health recommendations for Lp(a) measurement
- The ACTE Study
- LDL-C in the management of high cardiovascular risk, changing the paradigm for prevention
- Relationship Between LDL-C LLTs and Risk of Stroke
- Lipid Management in Patients with Diabetes Mellitus
- Should we encourage earlier and broader use of combination therapies in dyslipidemia?
- Odyssey outcomes - mortality
- Use of Lipid-Lowering Therapies Over 2 Years
- Prospective evaluation of lipid management following acute coronary syndrome in Saudi Arabia
- Lipid-Lowering Therapy and Achievement of Lipid Targets ESC and EAS Guidelines
- Lipid management in patients with ACS/ASCVD
- Importance of lipid registries in cardiovascular prevention
- Cardiovascular Disease in Saudi Arabia: Facts and the Way Forward
- NEJM Odyssey outcomes
- Act Now for Your ACS Patients: Patient Identification
- Optimal use of LLT after ACS
- Odyssey outcomes - CABG results
- Lp(a) and PCSK9 inhibition in nominally controlled LDL-C patients
- What do us physicians and patients think about LLTs and goals of treatment?
- Statin/Ezetimibe Combination VS Statin Monotherapy
- Improving Lipid Management for Patients Post-ACS
- The European experience: Swedeheart and AIFA registries
- Prognostic impact of achieving LDL cholesterol guidelines
- Possible Challenges Post One Year of ESC/EAS Guidelines
- Regulate LDL-C level for those undergoing coronary revascularization (Diabetic Patients)
- Dyslipidemia performance of 2016 2019 and 2021 ESC Dyslipidemia guidelines
- Perceptions and Barriers on the use of PCSK9 inhibitors
- Role of Genetic Testing in Management of Dyslipidemia
- Metabolic Risk Factors and Effect of Alirocumab on CV Events
- Clinical practice experience in patients with familial hypercholesterolemia (FH) from the Safeheart registry
- Managing Recurrent ASCVD risk of your ACS Patient: A call to Action – GULF Perspective: Part 2
- Approach for Patients with CAD: Focus on LDL-C Control
- Acute LDL-C Reduction Post ACS: Strike Early and Strike Strong: From Evidence to Clinical Practice
- Overview of adherence data with LLT highlighting the most recent data with PCSK9i
- Odyssey Outcomes - PVD Sub-analysis
- Effect of Alirocumab on MACE in patients with CKD
- PCSK9i and Prevention of CVD
- Management of Patients With Very High Cardiovascular Risk Eligible for PCSK9 Inhibitor Treatment: 1-year Outcomes of The PERI-DYS Study
- Evaluation of lipid management following ACS
- Event rates and Risk Factors for Recurrent CV Events
- ACC/AHA vs ESC/EAS LDL–C recommendations for residual risk reduction in ASCVD: A simulation study from Da Vinci
- EAS guidance regarding combining Lipid-modifying therapy
- PCSK9i after hospital discharge for acute MI
- Achievement of lipid modification goals with Statins & Ezetimibe
- Lipid-lowering therapy and care gap in patients with Familial Hypercholesterolemia
- Meta Analysis of apoB Lowering and CV Risk Reduction Among Different LLTs
- Atherosclerosis: Identifying risks and improving outcomes
- Odyssey outcomes - elderly patients results
- Odyssey outcomes - PVD results
- ESC Lp(a) in Clinical practice EAS Consensus statement
- Single-Pill Combinations in Dyslipidemia
- Real-life safety and efficacy of Alirocumab - Odyssey apprise study
- VTE Risk Assessment in Surgical Patients
- LLTs Exposure Time and Major Vascular Risk Reduction
- LDL-C The Only Causal Risk Factor for ASCVD
- CV Risk management in T1DM using guidelines
- Prospective evaluation of lipid management following ACS in Saudi Arabia (ACOSYM Study)
- Resources
- Events
- CardioRisk WebApp
- VTE Safety Zone: Primary VTE Prophylaxis in Patients with Cancer Undergoing Major Abdominal/Pelvic Surgery
- World Hypertension Day Ep. 2
- Dyslipidemia Expert Exchange: Best practice approaches in dyslipidemia management
- World Hypertension Day Ep. 1
- VTE Safety Zone: Assessing the VTE Risk in Hospital and Beyond
- Dyslipidemia Webisodes: Mortality data with Prof. Tunon
- Challenges of VTE Prophylaxis in Surgery
- Dyslipidemia Webinars: Optimizing Dyslipidemia management
- Hypertension and CVD
- Articles
- Thrombosis
- Articles
- Independent Risk Factors for Venous Thromboembolism
- Maternal and Perinatal Outcomes of VTE
- Changing trends in VTE: Pulmonary Embolism cases on Rise within the Last Decade
- Impact of anemia on long-term clinical outcomes in venous thromboembolism: Findings from GARFIELD-VTE registry
- Post Thrombotic Syndrome in Women
- Risk for Pulmonary Embolism Continues Beyond 6 Weeks of Surgery
- Risk for VTE is higher in emergency surgery than elective procedures
- No Rebound Effect Post Clopidogrel Withdrawal
- Insights and impacts from the TALOS-AMI Trial
- Low risk of VTE Following Early Pregnancy Loss in Pregnancies Conceived by IVF
- 2019 ESC Guidelines for Acute Pulmonary Embolism
- ASH 2019 Guidelines for Surgical Prophylaxis
- Trends in Pulmonary Embolism-related mortality in Europe
- Evaluation Of Comparative Efficacy and Safety of Thromboprophylaxis Agents Among Critically Ill Patients
- Incident heart failure tied to increased long-term risk for VTE
- Unmet clinical needs in the management of VTE in at-risk patients
- Clopidogrel as the standard of care for elective PCI: Findings from the Alpheus
- Sanofi Thrombosis Summit
- Risk factors of lower extremity DVT in patients undergone gynecological laparoscopic surgery
- Benefit of Prophylaxis for High-Risk Surgical Patients
- Global use of RAM and Thromboprophylaxis in hospitalized patients
- In hospital outcomes in young patients with AMI: Results from Gulf Coast
- VTE Comparison of Pregnancy - Specific Risk Scoring Systems in Hospitalized Maternity Patients
- Is Clopidogrel a viable first choice P2Y12 inhibitor for DAPT after PCI?
- Prolonged Thromboprophylaxis with LMWH after Abdominal or Pelvic Surgery
- Single Antiplatelet therapy: Insights on earlier use
- Utility of Pregnancy - Adapted Years Algorithm in Diagnosis of Pulmonary Embolism
- Safety profile of preoperative administration of low-molecular-weight heparin for Lung Cancer population
- What is the Thrombotic Risk vs Hemorrhagic Risk in Surgical Patients?
- Effect of de-escalated P2Y12 inhibitor switching in dual antiplatelet therapy (DAPT)
- DVT in Post-partum Case of Caesarean Section
- VTE Prophylaxis in Surgical Patients
- Recurrence of VTE in Patients with Recent Gestational DVT or PE
- Management of antithrombotic therapy in patients with AF undergoing PCI
- Risk for Post-operative Venous Thromboembolism in Patients Receiving Enoxaparin Prophylaxis
- VTE prophylaxis in medically ill patients
- Duration of thromboprophylaxis following major abdominopelvic cancer-related surgery
- Ticagrelor vs Clopidogrel in ACS patients undergoing PCI in routine clinical practice
- Ticagrelor vs Clopidogrel in Older Patients With ACS PCI
- DAPT in Elderly with CAD Meta Analysis
- Maternity Clot Risk Model to Predict Women at Risk of VTE
- VTE Safety Zone 2023 Program Highlights
- Understanding de-escalation in Antiplatelet therapy
- VTE & Bleeding risk assessment in surgical patients
- VTE incidence after cesarean delivery
- Pre vs post operative initiation of Thromboprophylaxis in Liver surgeries
- VTE Incidence after Cesarean Delivery in Selected Guidelines
- Evaluation Of Comparative Efficacy and Safety of Thromboprophylaxis Agents Among Critically Ill Patients
- Major GI Bleeding in VTE RIETE Analysis
- Adherence and persistence analysis in patients treated with DAPT
- Acute Medical Illness: Advanced Age Alone Predicts Venous Thromboembolism Similar to Existing Risk Assessment Models
- Specific Patient Characteristics Linked to Below Average Quality of Life in Patients with Recent Venous Thromboembolism (VTE)
- Effectiveness and safety of Clopidogrel vs Aspirin
- GAPS trial: Low-dose LMWH and GCS in in elective surgical inpatients at moderate or high risk VTE
- Thrombosis VTE SZ 2022 Summary Video
- Enoxaparin monotherapy vs UFH monotherapy among inpatients with NSTEMI
- Caprini Score Responses to Prevent VTE in Patients Undergoing Varicose Vein Surgery
- Events
- Articles
- Hypertension
- Dyslipidemia
- Neurology
- Multiple Sclerosis
- Articles
- Exercise as ”medicine” in the treatment of MS
- How old is your brain?
- MS Updates
- Cognitive decline – The invisible burden of MS?
- Slowing of brain atrophy with Teriflunomide
- Why has our brain suddenly become of interest?
- Measuring brain atrophy. What can be done and where are we heading?
- The importance of deep grey matter in MS
- Falling chronically ill – How do I cope and move forward?
- The reason for MS – beyond focal inflammation
- Thalamic atrophy as a new biomarker of MS? The predictive value and how to use in clinical practice
- Cognitive training – A curse or a blessing?
- A promising biomarker in MS: Neurofilament light chain
- Events
- Multiple Sclerosis Diagnosis and Misdiagnosis by Prof. Bassem Yamout
- Aubagio® - Impact on Brain Health and Real World Efficacy by Dr. Ahmed Shatila
- MSXChange l MS and Women
- Personalized Therapy in RMS - Which DMT to Use and When? Professor Peter Rieckmann
- Intro to Multiple Sclerosis by Dr Naji Riachi
- The Underlying Biology of Neuroinflammation
- A Patient's Journey on Teriflunomide: insights into Long-Term Treatment
- Articles
- Epilepsy
- Multiple Sclerosis
- Rare Disease
- Gaucher
- Fabry
- Other Rare Disease Topics
- Articles
- An overview of Lysosomal Storage Disorders & Sanofi`s Commitment to the Development and Provision of Treatments
- The role and importance of Patients Associations and Scientific societies ; Oman Experience
- Legacy Video for Rare Disease Academy
- Multidisciplinary approaches in Rare Disease Patient management
- LSDs overview
- The role and importance of Patients Associations and Scientific societies ; UAE experience
- What are the new diagnostics modalities used to expedite Rare Disease patients identification?
- Extraordinary measures: what are the benefits to have such movies talking about Rare Diseases?
- What is the role of Artificial Intelligence in accelerating patient's diagnosis?
- Meet a Sanofi Specialist
- How To Diagnose LSDs?
- What are Lysosomal Storage disorders?
- Lysosomal Storage Diseases from Neurology Perspective
- Multidisciplinary approaches in Rare Disease Patient management in KSA
- When shall we think of a rare disease from Neurological perspective
- The Stigma of Rare Diseases
- Events
- Articles
- Mucopolysaccharidosis Mps
- Acid Sphingomylenase Deficiency Niemann Pick
- Articles
- Inspiring Stories of Patients Living with ASMD
- What is ASMD?
- Respiratory Impairment in Acid Sphingomyelinase Deficiency (ASMD): A Case Report.
- Professor Moeen Al Sayed video on ASMD
- How is ASMD inherited?
- Impact of symptoms and risk of ASMD on patients and caregivers
- Differential diagnostics for ASMD in patients suspected to have GD
- Professor Tawfeq Ben Omran video on ASMD
- Management of ASMD - Expert opinion: Professor Tawfeq Ben Omran
- Uncover ASMD and GAUCHER
- ASMD
- Management of ASMD - Expert opinion: Professor Fatma Al- Jasmi
- Management of ASMD - Expert opinion: Professor Moeen Al Sayed
- Professor Fatma Al-Jasmi video on ASMD
- What Are the Signs and Symptoms of ASMD?
- How do you know if you or a loved one has ASMD?
- Consensus Guidelines for the Clinical Management of ASMD
- ASMD Phenotypes
- Events
- Articles
- Pompe
- Articles
- Expert Group Consensus From the Arabian Peninsula On the Diagnosis of Lopd
- Expert Group Consensus From The Arabian Peninsula On The Diagnosis Of Late Onset Pompe Disease for orthopedists
- IOPD Challenges
- Early diagnosis and management of IOPD
- Pompe Care Podcast Series
- Expert Group Consensus From the Arabian Peninsula On the Diagnosis of Lopd
- Prevalence Of LOPD In Patients With Undifferentiated Proximal Myopathy And Undiagnosed Muscle Biopsy
- Diagnostic challenges of LOPD
- Pompe
- Have you considered Pompe Disease?
- Pompe video
- Their Stories shaped them like Pearls
- Expert Group Consensus From The Arabian Peninsula On The Diagnosis Of Late Onset Pompe Disease (LOPD)
- Social stigma
- Differential Diagnosis Of Late Onset Pompe Disease (LOPD) and Myotonic Dystrophy Type 1 Through Abdominal Ultrasonography
- Experts recommendations on Late Onset Pompe Disease (LOPD) differential diagnosis from GCC
- Navigating the Pompe Disease Journey
- Articles
- Respiratory
- Asthma
- Articles
- How Type 2 inflammation affect patients with Asthma?
- FeNO Video
- Open Up a World Beyond Their Asthma Symptoms
- Dupixent® (dupilumab) Mechanism of Action
- How does Dupixent improve Asthma control and quality of live for Pediatric Patients?
- What gives you confidence that Dupixent improves patients’ quality of life?
- OCS Video
- Dose a Pediatric indication give you a confidence to prescribe Dupixent?
- Open up a world beyond their Asthma symptoms
- Consider Dupixent for Asthmatic patients with high EOS
- Why is it important to measure FEV1 in patients with asthma?
- How to inject Dupixent
- Severe Asthma Biomarker's
- Discover a solution to control mixed Eosinophilic and Allergic Asthma
- Asthma Control Tests (ACT) overview
- How does Dupixent target the underlaying type2 inflammation in asthma?
- About Type 2 Inflammation – Asthma
- What beneficial impact does Dupixent have on OCS-Dependent patients?
- How does Dupixent help reduce asthma exacerbations across multiple phenotype.
- FeNO Is a Clinically Useful Biomarker of Type 2 Inflammation in Pediatric Patients With Asthma
- Prevalence of Asthma
- How do you choose the right Biologic for a particular Asthma patients?
- Dupixent reduce Asthma Exacerbation across different type of patients
- What's possible when their Child's Asthma is under control?
- Asthma Assessment Tools (EPOS)
- Managing Severe Asthma and CRSwNP through the lens of type 2 inflammation
- Airway Hyperresponsiveness in Asthma
- What challenges do you face when treating patients with Type 2 inflammation?
- What is your experience with Dupixent in your practice?
- Consider Dupixent for Asthmatic patients with OCS use
- When do you discuss Biologic treatment with your Asthma patients?
- How do you balance the cost of Biologics with the value they can bring to patients?
- What feedback have you received from patients being treated with Dupixent?
- Lung Function Decline and Exacerbation in Asthma
- Why is it important to look for Type 2 inflammation in patients with Asthma?
- How does Dupixent support lung function improvement in Pediatric Asthma?
- Clinical Remission Video
- Articles
- Chronic Obstructive Pulmonary Disease (COPD)
- Chronic Rhinosinusitis With Nasal Polyps Crswnp
- Asthma
- Other topics
- Payor
- Articles
- cGVHD Burden
- Rezurock Efficacy
- Proven Safety of Dupixent® against Type 2 Inflammation
- Unmet Need
- Economic Burden of COPD in KSA
- Rezurock Dosage
- Proven Efficacy of Dupixent® against Type 2 Inflammation
- Rezurock Economic Value
- Clinical Burden of COPD
- Rezurock Safety
- Burdens of CSU
- Proven Efficacy of Dupixent® in COPD
- Articles
- Payor
- Vaccines
- Respiratory Syncytial Virus
- Articles
- RSV
- RSV Burden in Infants
- Implementing Beyfortus successfully
- Rattle
- 2024 RSV International Congress - ESPID
- Beyfortus in Action ECMMID
- RSV History
- Implementing Beyfortus successfully (ES)
- Implementing Beyfortus successfully (US)
- Saudi initiatives on Bronchiolitis Recommendations
- Nirsevimab : Clinical Experience
- 2024 RSV International Congress ECMMID
- Beyfortus®, an innovative immunization
- Nirsevimab International Recommendation
- Implementing Beyfortus successfully (FR)
- Burden of Disease
- Beyfortus in Action
- All Infant Protection
- Real World Evidence Impact of universal immunization with Nirsevimab
- Articles
- Influenza
- Respiratory Syncytial Virus
- Rare Blood Disorders
- Dermatology
- Bullous Pemphigoid
- Prurigo Nodularis
- Articles
- Mechanism of Prurigo Nodularis Disease
- There is significant unmet need in the management of PN¹
- Type 2 Inflammation may play a role in Prurigo Nodularis Pathophysiology¹
- Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials
- PN Expert Interview Series with Dr. Shawn Kwatra
- Prurigo Nodularis is a distinct, Chronic, Neural and Immune- Mediated skin disease characterized by intense itch and Nodular Lesions¹
- Articles
- Atopic Dermatitis
- Gastroenterology
- Transplant
- chronic GRAFT-VERSUS-HOST DISEASE (cGVHD)
- Articles
- Molecular Pathway
- Inflammation and Fibrosis Role
- European Respiratory Society (ERS)/ European Society for Blood and Marrow Transplantation (EBMT) clinical practice guidelines on treatment of pulmonary cGvHD in adults
- Treatment under Clinical Development
- Impact on Patients
- Other Treatment Options
- Psychological & Economical impact
- Understandig cGVHD
- Clinical outcomes of cGvHD following allogeneic HSCT: A Swedish population-based real-world registry study
- Optimizing Treatment
- Updated European Society of Blood and Marrow Transplantation consensus recommendations for GVHD prophylaxis and management in hematological malignancies after stem-cell transplantation
- Advances in the biology of chronic GVHD
- Articles
- chronic GRAFT-VERSUS-HOST DISEASE (cGVHD)
- Products
- Apidra®
- Praluent®
- Dupixent® Nasal Polyps
- Plavix®
- Nexviazyme®
- Xenpozyme®
- Soliqua®
- Cerezyme®
- Sarclisa®
- Aldurazyme®
- Cablivi®
- aTTP Sphere Digital Case Library
- Real-World Evidence Studies
- REACT-2020 and Aggregated Analysis
- aTTP-Related Events
- aTTP Diagnosis and Treatment
- Real World Evidence Studies/Spanish
- Real World Evidence Studies/Italian
- Delay in CABLIVI Start
- aTTP Sphere Digital Case Library - Kuwait
- CABLIVI Mechanism of Action
- Mechanism of Disease
- Recurrences
- Post-HERCULES
- ISTH TTP Guidelines
- HERCULES Study
- TTP Patient Case Study in UAE by Dr Hasan
- Delay in CABLIVI Start - Patient Outcomes
- HERCULES: Summary2
- TTP Patient Case Study in KSA
- Active Disease
- TTP Patient Case Study in UAE by Dr Hani Osman
- aTTP Sphere Digital Case Library - Qatar
- ISTH TTP Guidelines
- Healthcare Resource Utilization
- CABLIVI Safety Profile
- HERCULES STUDY
- Platelet Count Normalization
- CNR-MAT Registry Study
- Early Treatment Initiation
- CABLIVI-Specific Treatment Recommendation1
- SoloSmart®
- Rezurock®
- Aprovasc®
- Xatral®
- Solian®
- Myozyme®
- Fabrazyme®
- Dupixent® Atopic Dermatitis
- Renvela®
- Dupixent® Prurigo Nodularis
- Toujeo®
- Clexane®
- Aubagio®
- Zympass®
- Scientific Content
- Sitemap
- Sign Up
- Sign In
- Legal notice
- Privacy Policy
- Cookie Policy